Advertisement

Analysis of Risk of Bleeding Complications After Different Doses of Aspirin in 192,036 Patients Enrolled in 31 Randomized Controlled Trials

      We sought to compare the risk of hemorrhage due to the low (<100 mg), moderate (100 to 200 mg), and high (>200 mg) doses of aspirin (acetylsalicylic acid [ASA]) in 192,036 patients enrolled in 31 clinical trials. Despite substantial differences in the reporting patterns of bleeding complications, low-dose ASA was associated with the lowest risk, and moderate doses caused a relatively high hemorrhagic event rate, especially with regard to minor, gastrointestinal, and total bleeding, and stroke. These findings should be considered when using combination antiplatelets, anticoagulant therapy, or both, with ASA, especially with the daily dose of >100 mg.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Serebruany V.L.
        • Malinin A.I.
        • Eisert R.M.
        • Sane D.C.
        Risk of bleeding complications with antiplatelet agents: a meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials.
        Am J Hematol. 2004; 75: 40-47
        • CURE Trial Investigators
        Effect of clopidogrel in addition to aspirin in patients with acute coronary syndrome without ST-segment elevation.
        N Engl J Med. 2001; 345: 494-502
        • Peters R.J.
        • Mehta S.R.
        • Fox K.A.
        • Zhao F.
        • Lewis B.S.
        • Kopecky S.L.
        • Diaz R.
        • Commerford P.J.
        • Valentin V.
        • Yusuf S.
        • Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators
        Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
        Circulation. 2003; 108: 1682-1687
        • Topol E.J.
        • Easton D.
        • Harrington R.A.
        • Amarenco P.
        • Califf R.M.
        • Graffagnino C.
        • Davis S.
        • Diener H.C.
        • Ferguson J.J.
        • Fitzgerald
        • et al.
        • Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators
        Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.
        Circulation. 2003; 108: 399-406
        • Antithrombotic Trialists' Collaboration
        Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
        BMJ. 2002; 324: 71-86
        • Rao A.K.
        • Pratt C.
        • Berke A.
        • Jaffe A.
        • Ockene I.
        • Schreiber T.L.
        • Bell W.R.
        • Knatterud G.
        • Robertson T.L.
        • Terrin M.L.
        Thrombolysis in Myocardial Infarction (TIMI) Trial—phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.
        J Am Coll Cardiol. 1988; 11: 1-11
        • The GUSTO Investigators
        An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
        N Engl J Med. 1993; 329: 673-682
        • The Dutch TIA Trial Study Group
        A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke.
        N Engl J Med. 1991; 325: 1261-1266
        • Diener H.C.
        • Cunha L.
        • Forbes C.
        • Sivenius J.
        • Smets P.
        • Lowenthal A.
        European Stroke Prevention Study 2.
        J Neurol Sci. 1996; 143: 1-13
        • Juul-Moller S.
        • Edvardsson N.
        • Jahnmatz B.
        • Rosen A.
        • Sorensen S.
        • Omblus R.
        Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris.
        Lancet. 1992; 340: 1421-1425
        • Hansson L.
        • Zanchetti A.
        • Carruthers S.G.
        • Dahlof B.
        • Elmfeldt D.
        • Julius S.
        • Menard J.
        • Rahn K.H.
        • Wedel H.
        • Westerling S.
        Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.
        Lancet. 1998; 351: 1755-1762
        • The Medical Research Council's General Practice Research Framework
        Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk.
        Lancet. 1998; 351: 233-241
        • The SALT Collaborative Group
        Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events.
        Lancet. 1991; 338: 1345-1349
        • Taylor D.W.
        • Barnett H.J.
        • Haynes R.B.
        • Ferguson G.G.
        • Sackett D.L.
        • Thorpe K.E.
        • Simard D.
        • Silver F.L.
        • Hachinski V.
        • Glagett C.P.
        • et al.
        Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial.
        Lancet. 1999; 353: 2179-2184
        • Collaborative Group of the primary Prevention Project
        Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice.
        Lancet. 2001; 357: 89-95
        • Second SYMPHONY Investigators
        Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes.
        Circulation. 2001; 103: 1727-1733
        • The SYMPHONY Investigators
        Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomized trial.
        Lancet. 2000; 355: 337-345
        • Scrutinio D.
        • Cimminiello C.
        • Marubini E.
        • Pitzalis M.V.
        • Di Biase M.
        • Rizzon P.
        Ticlopidine versus Aspirin after Myocardial Infarction (STAMI) trial.
        J Am Coll Cardiol. 2001; 37: 1259-1265
        • Pulmonary Embolism Prevention (PEP) Trial Collaborative Group
        Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial.
        Lancet. 2000; 355: 1295-1302
        • Coumadin Aspirin Reinfarction Study (CARS) Investigators
        Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction.
        Lancet. 1997; 350: 389-396
        • CAST (Chinese Acute Stroke Trial) Collaborative Group
        CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke.
        Lancet. 1997; 349: 1641-1649
        • Fiore L.D.
        • Ezekowitz M.D.
        • Brophy M.T.
        • Lu D.
        • Sacco J.
        • Peduzzi P.
        • Combination Hemotherapy And Mortality Prevention (CHAMP) Study Group
        Department of Veterans Affairs Cooperative Studies Program Clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study.
        Circulation. 2002; 105: 557-563
        • EAFT (European Atrial Fibrillation Trial) Study Group
        Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke.
        Lancet. 1993; 342: 1255-1262
        • Gullov A.L.
        • Koefoed B.G.
        • Petersen P.
        Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study.
        Arch Intern Med. 1999; 159: 1322-1328
        • Multicentre Acute Stroke Trial–Italy (MAST-I) Group
        Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke.
        Lancet. 1995; 346: 1509-1514
        • UK-TIA Study Group
        United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results.
        J Neurol Neurosurg Psychiatry. 1991; 54: 1044-1054
        • Leon M.B.
        • Baim D.S.
        • Popma J.J.
        • Gordon P.C.
        • Kutlip D.E.
        • Ho K.K.
        • Giambartolamei A.
        • Diver D.J.
        • Lasorda D.M.
        • Wiliams D.O.
        • et al.
        A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting.
        N Engl J Med. 1998; 339: 1665-1671
        • The International Stroke Trial (IST) Group
        A randomised trial of aspirin, subcutaneous heparin, both or neither among 19 435 patients with acute ischaemic stroke.
        Lancet. 1997; 349: 1569-1581
        • Manson J.E.
        • Stampfer M.J.
        • Colditz G.A.
        • Willett W.C.
        • Rosner B.
        • Speizer F.E.
        • Hennekens C.H.
        A prospective study of aspirin use and primary prevention of cardiovascular disease in women.
        JAMA. 1991; 266: 521-527
        • Steering Committee of the Physicians' Health Study Research Group
        Final Report on the aspirin component of the ongoing physicians' health study.
        N Engl J Med. 1998; 321: 129-135
      1. SPAF Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Stroke Prevention in Atrial Fibrillation II study. Lancet 1994;343:687–691.

        • Baigent C.
        • Collins R.
        • Appleby P.
        • Parish S.
        • Sleight P.
        • Peto R.
        ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither.
        BMJ. 1998; 316: 1337-1343
        • CAPRIE Steering Committee
        A randomised, blinded trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE).
        Lancet. 1996; 348: 1329-1339
        • Steinhubl S.R.
        • Berger P.B.
        • Mann III, J.T.
        • Fry E.T.
        • DeLago A.
        • Wilmer C.
        • Topol E.J.
        Clopidogrel for the reduction of events during observation.
        JAMA. 2002; 288: 2411-2420
        • Mohr J.P.
        • Thompson J.L.
        • Lazar R.M.
        • Levin B.
        • Sacco R.L.
        • Furie K.L.
        • Kistler J.P.
        • Albers G.W.
        • Pettigrew L.C.
        • Adams H.P.
        • et al.
        A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.
        N Engl J Med. 2001; 345: 1444-1451
        • Prevention in Atrial Fibrillation Investigators
        Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study.
        JAMA. 1998; 279: 1273-1277
        • Hass W.K.
        • Easton J.D.
        • Adams Jr, H.P.
        • Pryse-Phillips W.
        • Molony B.A.
        • Anderson S.
        • Kamm B.
        A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients.
        N Engl J Med. 1989; 321: 501-507
        • Antithrombotic Trialists Collaboration
        Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
        BMJ. 2002; 324: 71-86
        • Roffi M.
        • Mukherjee D.
        • Chew D.P.
        • Bhatt D.L.
        • Cho L.
        • Robbins M.A.
        • Ziada Z.M.
        • Brennan D.M.
        • Ellis S.G.
        • Topol E.J.
        Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials.
        Circulation. 2002; 106: 3063-3067